Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.

Kim JS, Lee HJ, Sung JD, Kim HJ, Lee SY, Kim JS.

Clin Appl Thromb Hemost. 2014 Oct;20(7):723-8. doi: 10.1177/1076029613485153. Epub 2013 Apr 23.

PMID:
23615295
2.

Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.

Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS.

Ann Pharmacother. 2011 Jul;45(7-8):861-8. doi: 10.1345/aph.1Q161. Epub 2011 Jun 28.

PMID:
21712506
3.

Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.

Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, Choi HA.

J Clin Pharm Ther. 2016 Oct;41(5):499-502. doi: 10.1111/jcpt.12415. Epub 2016 Jul 6.

PMID:
27381025
4.

Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.

Vandiver JW, Vondracek TG.

Pharmacotherapy. 2012 Jun;32(6):546-58. doi: 10.1002/j.1875-9114.2011.01049.x. Epub 2012 Apr 24. Review.

PMID:
22531940
5.

Comparison of two nomograms of unfractionated heparin in patients with acute coronary syndrome.

Modares Mosadegh M, Sadr Bafghi SM.

Acta Med Iran. 2013 Mar 16;51(2):87-93.

6.

[Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].

Mariné L, Sánchez G, Vargas JF, Zúñiga P, Aizman A, Mertens R, Bergoeing M, Muñoz B.

Rev Med Chil. 2014 Nov;142(11):1392-7. doi: 10.4067/S0034-98872014001100005. Spanish.

7.

Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.

Kearon C, Harrison L, Crowther M, Ginsberg JS.

Thromb Res. 2000 Mar 15;97(6):395-403.

PMID:
10704648
8.

Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.

Frugé KS, Lee YR.

Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S90-7. doi: 10.2146/sp150016.

PMID:
26272899
9.

Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.

Trucco M, Lehmann CU, Mollenkopf N, Streiff MB, Takemoto CM.

J Thromb Haemost. 2015 May;13(5):788-94. doi: 10.1111/jth.12890. Epub 2015 Apr 13.

10.

Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.

Bauer SR, Ou NN, Dreesman BJ, Armon JJ, Anderson JA, Cha SS, Oyen LJ.

Mayo Clin Proc. 2009 Dec;84(12):1073-8. doi: 10.4065/mcp.2009.0220.

11.

Monitoring of unfractionated heparin in critically ill patients.

Aarab R, van Es J, de Pont AC, Vroom MB, Middeldorp S.

Neth J Med. 2013 Nov;71(9):466-71. Review.

12.

Heparin dose adjustment required to maintain goal-activated partial thromboplastin time during therapeutic hypothermia.

Fevold RT, Leung YT, Garofoli AC, White RD, Barsness GW, Dierkhising RA, Ou NN.

J Crit Care. 2015 Jun;30(3):574-8. doi: 10.1016/j.jcrc.2015.01.016. Epub 2015 Jan 29.

PMID:
25746584
13.

Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.

Fuentes A, Gordon-Burroughs S, Hall JB, Putney DR, Monsour HP Jr.

Ther Drug Monit. 2015 Feb;37(1):40-4. doi: 10.1097/FTD.0000000000000105.

PMID:
24901494
14.

A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.

Vandiver JW, Vondracek TG.

Hosp Pract (1995). 2013 Apr;41(2):16-24. doi: 10.3810/hp.2013.04.1022. Epub 2013 Apr 1.

PMID:
23545756
15.

Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity.

Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K.

Surg Obes Relat Dis. 2008 Nov-Dec;4(6):748-53. doi: 10.1016/j.soard.2008.03.005. Epub 2008 Jun 30.

PMID:
18586569
16.

Comparison of 2 weight-based heparin dosing nomograms in neurology and vascular surgical patients.

Marotti SB, Barras M, Kirkpatrick C.

Ther Drug Monit. 2015 Feb;37(1):33-9. doi: 10.1097/FTD.0000000000000099.

PMID:
24831654
17.

Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.

Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL.

Ann Pharmacother. 2013 Feb;47(2):151-8. doi: 10.1345/aph.1R635. Epub 2013 Feb 5.

PMID:
23386070
18.

Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms.

Miller AE, Montague D, Rodgers JE, Sanghvi S, Whinna HC, Krumnacher H.

Am J Health Syst Pharm. 2011 May 15;68(10):893-8. doi: 10.2146/ajhp100321.

PMID:
21546640
19.

Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation.

Shalansky KF, FitzGerald JM, Sunderji R, Traboulay SJ, O'Malley B, McCarron BI, Naiman S.

Pharmacotherapy. 1996 Nov-Dec;16(6):1076-84.

PMID:
8947981
20.

Supplemental Content

Support Center